Clinical trials: Cystic Fibrosis-related Diabetes
Cystic Fibrosis
Glycemic Monitoring in Cystic Fibrosis
Current guidelines on the diagnoses and management of cystic fibrosis (CF) related diabetes recommend treatment for diabetes based on diagnostic criteria derived from adults with type 2 diabetes.
- Trial name
- GEM (NCT02211235)
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis, Pancreatic Insufficiency
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that characterizes cystic…
- Conditions
- Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
- Trial name
- NCT04731272
- Testing
- Dulaglutide 0.75Mg/0.5Ml Inj Pen
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Pennsylvania
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis
Cystic Fibrosis (CF) related diabetes (CFRD) is a unique form of diabetes mellitus, different from type 1 diabetes and type 2 diabetes.
- Trial name
- NCT06560463
- Testing
- Access to Dexcom G7 CGM Data
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Cystic Fibrosis-related Diabetes
β-cell Function and Insulin Sensitivity in Patients With Cystic Fibrosis
Cystic fibrosis is a genetic disorder caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, leading to pulmonary infections, sinus disease, pancreatic insufficiency, hepatobiliary disease and…
- Trial name
- NCT04379726
- Testing
- therapeutic optimization
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes
This project is designed to begin to characterize the abnormalities of glucagon secretion in subjects with cystic fibrosis related diabetes along the spectrum of glucose tolerance.
- Trial name
- NCT02398383
- Testing
- Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Yale University
Cystic Fibrosis
Development of Diabetes in Adults With Cystic Fibrosis (CF)
This is a crossover study to determine the possible factors that might be related to the development of diabetes in CF and examines the relationship between pancreatic fatigue if any, and the development of diabetes.
- Trial name
- CF-DIABETES (NCT03644199)
- Testing
- Oral Glucose Tolerance Test (OGTT) assessment arm, Mixed meal test evaluation test arm
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
Cystic Fibrosis Related Diabetes
Genetic Modifiers of Cystic Fibrosis Related Diabetes
This research is being done to find the genes and other factors that are responsible for differences among persons with cystic fibrosis.
- Trial name
- NCT01113216
- Where
- 3 sites in United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Diabetes, Cystic Fibrosis
Training in Shared Decision-making of Cystic Fibrosis Centers Competences in the Treatment of CF Related Diabetes in Adult Patients
Diabetes affects half of cystic fibrosis patients aged 30 years and older. It develops asymptomatically for a long time. Also, two options are possible: start insulin treatment now with the additional constraints associated with…
- Trial name
- FORAIDMUCO (NCT04891159)
- Testing
- Shared decision making
- Where
- 4 sites in France
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
A CFit Study - Baseline
A great medical success is the increase in the median survival age associated with cystic fibrosis (CF). However, this success has led to a new era of research with the aim to maximise the quality of life (QoL) of the aging CF…
- Trial name
- NCT03234387
- Testing
- No intervention - only assessments.
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Portsmouth
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Cardiac Structure and Function in Patients with Cystic Fibrosis
In a prospective observational cohort study (n = 100), the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and cystic fibrosis genotype and severity and determine whether these…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis, Pulmonary, Cystic Fibrosis of Pancreas
- Trial name
- NCT06084468
- Where
- 2 sites in Denmark
- Volunteers
- 104 people
- Sponsor
- Herlev and Gentofte Hospital
Cystic Fibrosis
Sitagliptin in Cystic Fibrosis-Related Diabetes
The purpose of this study is to determine whether the dipeptidyl peptidase IV (DPPIV) inhibitor sitagliptin is effective in the treatment of cystic fibrosis-related diabetes (CFRD).
- Trial name
- NCT01257464
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University of British Columbia
CF - Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis
This study proposes to examine the relationship between the development of impaired glucose tolerance, the phenotype of CFLD, and risk of liver fibrosis.
- Conditions
- CF - Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis Liver Disease
- Trial name
- NCT05229640
- Testing
- Fibroscan
- Where
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
Type 1 Diabetes, Type 2 Diabetes
ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2
The purpose of this study is to determine if use of a nonmydriatic fundus camera using autonomous artificial intelligence software at the point of care increases the proportion of underserved youth with diabetes screened for…
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Cystic Fibrosis-related Diabetes
- Trial name
- ACCESS2 (NCT05463289)
- Testing
- Point of Care Autonomous AI diabetic retinopathy exam
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Johns Hopkins University
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function
The purpose of this study is to assess the efficacy of metformin to improve airway ion channel function in those with CF-related diabetes (CFRD)
- Trial name
- NCT04530383
- Testing
- Metformin Hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
Cystic Fibrosis
Comparing Laboratory Blood Glucose Results With HemoCue Glucose 201 RT
There are very few studies comparing the accuracy, sensitivity and specificity of HemoCue glucose 201 RT system with the laboratory gold standard.
- Trial name
- CFRD (NCT01883037)
- Testing
- Blood glucose results
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Nutritional Intervention and Glycemic Improvement in Patients With Pre-diabetic Cystic Fibrosis.
Cystic fibrosis (CF) is a genetic disease with an autosomal recessive, chronic and progressive character about 10 to 25% of patients develop CF-related diabetes (DRFC).
- Trial name
- NCT03205904
- Testing
- Diet
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Cystic Fibrosis-related Diabetes, Cystic Fibrosis Pulmonary Exacerbation
Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management
This research proposes a pilot study using the combination of continuous glucose monitor (CGM) and insulin pump therapy, also known as sensor augmented pump (SAP) therapy, for cystic fibrosis related diabetes (CFRD) management in…
- Conditions
- Cystic Fibrosis-related Diabetes, Cystic Fibrosis Pulmonary Exacerbation, Cystic Fibrosis in Children
- Trial name
- NCT03939065
- Testing
- Sensor Augmented Pump Therapy, Standard of Care with CGM
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Simplification of CF-related Diabetes Screening at Home
Cystic fibrosis (CF)-related diabetes (CFRD) is the most common complication after pulmonary complications. This specific form of diabetes is associated with an increased morbidity and mortality.
- Trial name
- AtHome (NCT03227094)
- Testing
- Standard OGTT, Home-based OGTT (Beverage), Home-based OGTT (Candy)
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Performance and Patient Acceptance of a Commercially Available Beverage as Compared to an Oral Glucose Solution for Oral Glucose Tolerance Tests in Cystic Fibrosis (CF) Patients Who Are Screened for CF-related Diabetes.
Rationale: Cystic fibrosis (CF) is an incurable genetic disease that affects the pulmonary system, digestive system, reproductive system and the sweat glands.
- Trial name
- NCT05377502
- Testing
- OGTT
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)